Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
Wave Life Sciences will continue developing its RNA‑editing candidate WVE‑006 for alpha‑1 antitrypsin deficiency (AATD) after GSK relinquished its stake, aiming for accelerated regulatory feedback by mid‑2026. The AATD market, valued at $2.6 billion today, is projected to reach $6.2 billion by 2032, creating strong commercial incentives. Competitors include Beam Therapeutics’ base‑editing BEAM‑302, which is pursuing accelerated approval, and Tessera Therapeutics’ gene‑editing TSRA‑196 backed by Regeneron. Recent setbacks, such as Korro Bio’s KRRO‑110 failure, underscore the high‑risk nature of the space but leave room for multiple winners.
Intelligent Sensors Created for Quality-Assured Cell Production
Fraunhofer’s Center for Sensor Intelligence has unveiled the Multimodal Autonomous Sensor Platform (MAUS), an intelligent sensor suite that continuously monitors 3D cell‑spheroid production in bioreactors. The system combines electrochemical probes for glucose, lactate, dissolved oxygen, pH and temperature with dual‑camera...
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
Novo Nordisk announced Phase 3 results for its combination injection CagriSema, showing superior glycemic control and greater weight loss than Wegovy in patients with type 2 diabetes and obesity. In the 68‑week trial of more than 2,700 participants, CagriSema lowered HbA1c by...
Wnt Inhibitory Factor 1 Boosts Angiogenesis Under Hypoxia
Researchers discovered that silencing Wnt Inhibitory Factor 1 (WIF1) markedly boosts angiogenic activity in human umbilical vein endothelial cells exposed to hypoxic stress. The inhibition lifts repression on the Wnt pathway, leading to elevated VEGF and other pro‑angiogenic markers. In‑vitro experiments...
Infants’ Ventrotemporal Cortex Shows Rich Visual Categories
A new neuroimaging study shows that infants as young as six months possess a richly organized ventrotemporal cortex capable of distinguishing visual categories such as faces, objects, and scenes. Functional MRI scans revealed distinct, adult‑like activation patterns for each category,...
UK Body Raps Sanofi for Disparaging Pfizer's RSV Jab
Sanofi was found to have breached the UK pharmaceutical code after its chief executive, Paul Hudson, made unbalanced statements in an Observer interview comparing the company’s RSV antibody Beyfortus with Pfizer’s vaccine Abrysvo. The Prescription Medicines Code of Practice Authority...
FBI Raids Mysterious Biological Lab
Federal agents and local police raided a Las Vegas residence suspected of housing a clandestine biological laboratory, uncovering refrigerators filled with vials of unknown liquids. The operation is tied to a broader, multi‑agency investigation that may connect the site to...
Cutting-Edge Surgical Technique Reduces Ovarian Cancer Risk by Nearly 80%
A recent multi-center study shows that opportunistic salpingectomy, performed during routine benign gynecologic surgeries, reduces the risk of tubo‑ovarian carcinoma by nearly 80 percent. The analysis, spanning over 15,000 women and a median follow‑up of 12 years, found no increase...
Broad Antibody Shields Against Gammaherpesvirus gB
Researchers have identified a set of broadly neutralizing antibodies that target the conserved glycoprotein B (gB) of gammaherpesviruses. The antibodies bind multiple viral strains, blocking entry in cell culture and reducing viral load in mouse models. Structural analysis revealed a...
Gonadal Transcriptome Revealed in Siberian Sturgeon Development
Researchers have mapped the gonadal transcriptome across key developmental stages of the Siberian sturgeon, a species prized for caviar and aquaculture. Using high‑throughput RNA sequencing, they identified stage‑specific gene expression patterns governing sex differentiation, gametogenesis, and hormonal regulation. The dataset...
EMA Recommends Rezurock for Chronic Graft-Versus-Host Disease
The European Medicines Agency has issued a recommendation for conditional marketing authorization of Sanofi Winthrop’s Rezurock (belumosudil) to treat chronic graft‑versus‑host disease in patients aged 12 and older. In an open‑label study, 73% of participants achieved a response, with 44%...
Death Clock Launches ‘Life Lab’: An AI Health Concierge Democratizing Private-Doctor Level Care For The Mass Market
Death Clock has introduced Life Lab, an AI‑driven health concierge that combines lab testing, medical records, and longevity research to move care from reactive treatment to proactive prevention. The platform partners with more than 4,800 Labcorp, Quest and BioReference locations,...
GSK Returns Rights to Wave's RNA Editing Program for AATD
GlaxoSmithKline has terminated its collaboration with Wave Life Sciences, returning all rights to the RNA‑editing program aimed at treating alpha‑1 antitrypsin deficiency (AATD). The decision ends a partnership that was closely watched as a potential first‑in‑class RNA‑editing therapy. GSK will...
FDA Rejects Aquestive's Allergy Drug over Packaging Issues
The U.S. Food and Drug Administration issued a complete response letter to Aquestive Therapeutics, rejecting its allergy medication because of packaging deficiencies. The agency identified labeling and child‑resistance failures that do not meet federal standards. As a result, the drug’s...
Sonocatalytic Eradication of Hepatocellular Carcinoma by Tailoring Structural Defects of Black Indium Oxide Sonocatalysts and Leveraging Apoptosis/Ferroptosis‐Hybridized Pathways
Researchers engineered palladium‑integrated indium oxide with abundant structural defects to create a high‑performance sonocatalyst for hepatocellular carcinoma. The Pd component provides catalase‑like and peroxidase‑like activities, relieving tumor hypoxia and increasing hydroxyl‑radical generation under ultrasound. This dual action triggers a synergistic...
AI‐Guided Design of pH‐ and Redox‐Responsive Lignin@GO@ZIF‐8 Nanocarriers for Targeted Co‐Delivery of 5‐Fluorouracil and Metformin in Prostate Cancer Therapy
Researchers employed an AI‑guided workflow to engineer pH‑ and redox‑responsive Lignin@GO@ZIF‑8 nanocarriers that co‑deliver 5‑fluorouracil and metformin for prostate cancer treatment. Machine‑learning models, particularly XGBoost trained on 500 formulation data points, achieved R² values of 0.86‑0.89 for predicting drug loading,...
FDA Opens Submissions for PreCheck Program to Speed up US Factory Builds
The U.S. Food and Drug Administration has opened the first round of submissions for its new PreCheck program, designed to accelerate the construction and approval of drug manufacturing facilities. By allowing manufacturers to submit detailed construction plans early, the initiative...
Enhanced Voting Strategy for Date Palm Nutrient Classification
Researchers have introduced an enhanced voting strategy to classify nutrient profiles in date palm crops more accurately. The ensemble approach merges spectral imaging, chemical assays, and machine‑learning classifiers, lifting overall accuracy to roughly 94 percent. Validation across multiple orchards showed...
ConcertAI Launches Accelerated Clinical Trials, Leveraging Agentic AI to Radically Shorten Trial Timelines
ConcertAI unveiled Accelerated Clinical Trials (ACT), an enterprise platform powered by its CARAai agentic AI, to automate end‑to‑end trial processes. The solution claims to shorten overall trial timelines by 10‑20 months and cut design and amendment costs by roughly half....
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
GSK has returned Wave Life Sciences' RNA‑editing oligonucleotide WVE‑006 after a modest Phase Ib/IIa readout for alpha‑1 antitrypsin deficiency. The September data showed 11.9 µM AAT, slightly below analyst expectations, prompting GSK to refocus on larger indications like COPD. Despite the...
Amarin V. Hikma: Settling the Skinny Label Question
The U.S. Supreme Court has agreed to hear Amarin Pharma’s claim that Hikma Pharmaceuticals’ skinny‑label generic of Vascepa induces infringement of Amarin’s patented cardiovascular indication. The dispute centers on whether generic marketing that references the branded drug’s market size can...
Evaluating Fixed-Duration Regimens in Chronic Lymphocytic Leukemia
A recent narrative review by Dr. J.N. Allan evaluates fixed‑duration (FD) regimens in chronic lymphocytic leukemia, contrasting them with traditional indefinite therapies. Early clinical data show that FD schedules can achieve deep remissions while reducing side‑effects and treatment time. However,...
MRNA Vaccines Beat Haemozoin Block in Malaria
Researchers have demonstrated that next‑generation mRNA vaccines can neutralize the haemozoin barrier that malaria parasites use to evade host immunity. Preclinical trials in murine models showed a 78% reduction in parasitemia compared with conventional protein subunit vaccines. The mRNA platform...
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
The FDA issued a complete response letter rejecting Corcept Therapeutics' relacorilant for hypercortisolism, citing significant review issues identified early in the submission process. While the Phase III GRACE trial met its primary endpoint, the agency questioned the hypertension data and warned...
Unraveling DEHP’s Role in Allergic Rhinitis
A new study by Tang, Guo and Zhang applies network toxicology and molecular dynamics to map how the plasticizer DEHP and its metabolite MEHP interact with immune‑related proteins. The research identifies specific molecular pathways that link DEHP exposure to the...
Tailoring CRISPR–Cas PAM Specificity via AI Models
Researchers have unveiled AI-driven models that accurately predict and redesign protospacer adjacent motif (PAM) sequences for a wide range of CRISPR‑Cas enzymes. The platform leverages deep learning on millions of natural and synthetic PAM datasets, achieving up to 40% reduction...
FDA Knocks Back Pharming's Bid for Wider Joenja Use
The U.S. Food and Drug Administration issued a complete response letter rejecting Pharming's request to extend Joenja (leniolisib) to children aged four to 11 with activated phosphoinositide 3‑kinase delta syndrome (APDS). The agency flagged potential under‑exposure in lower‑weight pediatric patients...
Women in STEM: Inspiration From Innovators in Pharma
PharmTech interviewed Katy MacLellan, Technical Team Leader at Symbiosis, about her journey from a Scottish island to senior roles at Pfizer, Eli Lilly, CSL Seqirus and now Symbiosis. She highlights how female mentorship and visible STEM programs propelled her career and how companies...
Mixed Data Mars Sanofi's Venglustat Programme
Sanofi announced that its oral glucosylceramide synthase inhibitor venglustat achieved statistically significant neurological improvements in a Phase 3 trial for type 3 Gaucher disease, prompting regulatory filing plans. The same drug failed to demonstrate efficacy in a Fabry disease study, adding to...
Sanofi’s Venglustat Succeeds in Phase 3 Gaucher Trial but Fails Separate Study in Fabry Disease
Sanofi’s substrate‑reduction therapy venglustat met its primary endpoint in a Phase 3 trial for type 1 Gaucher disease, showing statistically significant reductions in glucosylceramide levels and improved organ volumes. The study enrolled 400 patients across North America and Europe and demonstrated a...
BIO Tells Congress How to Maintain US Biotech Leadership
BIO submitted a statement to the House Ways & Means Trade Subcommittee urging Congress to adopt policies that preserve U.S. biotech leadership. The organization highlighted the sector’s explosive growth, projecting a $4.25 trillion global market by 2033, and called for expanded...
Identifying GATA Transcription Factors in Cucurbitaceae Under Stress
Researchers have performed a genome‑wide survey of GATA transcription factors in major cucurbit crops, including cucumber, melon, watermelon, pumpkin, and squash. The study identified 30 GATA genes and mapped their chromosomal locations, revealing conserved zinc‑finger domains typical of the family....
FDA Launches Pilot Programme to Boost US Manufacturing
The FDA has opened its PreCheck pilot, a two‑phase program designed to speed regulatory approval for new pharmaceutical manufacturing sites in the United States. The agency will select facilities this year based on national‑priority products, development stage, and timeline to...
UCB Bags First EU Approval for Rare Genetic Disease TK2d
UCB’s Kygevi (doxecitine and doxribtimine) received a CHMP recommendation for EU approval, targeting thymidine kinase 2 deficiency (TK2d) in patients whose disease began before age 12. The drug already secured FDA approval last November and is slated for launch in the...
Unlocking Tumor Lymph Node Metastasis with Single-Cell Omics
Researchers applied single-cell omics to dissect lymph‑node metastasis in solid tumors, revealing distinct cellular subpopulations that drive spread. The study identified a set of mutation‑linked gene signatures that correlate with aggressive dissemination and uncovered novel surface markers for early detection....
Evaluating 3D vs Conventional Simulators for Cricothyrotomy
A recent multi‑institutional study compared 3D‑printed cricothyrotomy simulators with conventional mannequin models. Participants using the 3D devices completed the airway access procedure 15% faster and demonstrated higher tactile realism. The research also highlighted a 40% reduction in per‑unit cost for...
AstraZeneca Begins Trading on the New York Stock Exchange
AstraZeneca has begun trading its ordinary shares on the New York Stock Exchange under the ticker AZN, joining its existing listings on the London Stock Exchange and Nasdaq Stockholm. The move creates a harmonised listing structure, giving U.S. investors direct...
Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity
Researchers have engineered an M13 filamentous phage vector, termed SCP, that simultaneously displays dendritic‑cell targeting peptides and SpyCatcher proteins for antigen conjugation. In vitro, SCP activates dendritic cells, increasing co‑stimulatory markers and inflammatory gene signatures, which translates into enhanced cytotoxic...
Novel Wide‐Spectrum Virucidal Lipid Nanoparticles
POSTAN is a novel lipid‑based nanoparticle that acts as a broad‑spectrum virucidal agent. Composed of polyoxyethylene sorbitan oleate and sodium taurodeoxycholate, it mimics host heparan sulfate and lipid rafts to disrupt viral envelopes. In cell cultures and mouse models, POSTAN...
Novel Wide‐Spectrum Virucidal Lipid Nanoparticles (Small 7/2026)
Researchers Yugo Araújo Martins, Caroline Tapparel and colleagues introduced POSTAN, a lipid‑based nanoparticle that mimics heparan sulfate proteoglycans and viral lipid rafts. By exploiting the same entry pathways viruses use, POSTAN physically disrupts viral envelopes, halting replication. The platform showed...
Two‐Photon Polymerized 3D Geometries to Study Single‐Cell Mechanotransduction and Force Generation in Mesenchymal Stromal Cells
Researchers introduced a two‑photon polymerization direct‑laser‑writing platform that fabricates microscale 3D cages to confine single mesenchymal stromal cells. The cages enable nanometer‑scale traction‑force measurements while independently controlling cell volume and shape. Experiments showed that pure 3D geometry triggers vertical actin...
Fern‐Leaf‐Inspired Multifunctional Flexible Strain Sensors for Motion Monitoring, Information Communication and Health Alert
Researchers have developed a high‑performance flexible strain sensor inspired by fern leaves, employing reverse‑molding and film deposition to create hierarchical veins and a deep W‑shaped groove. The design generates staggered cracks and serpentine conductive paths, delivering a sensitivity of up...
Rationally Designed Oxidase‐Mimicking Nanozymes for Correlating Drug Resistance and Cellular Senescence with Total Antioxidant Capacity
Researchers engineered a core‑shell MnO2@ZIF-67 nanozyme that exhibits markedly superior oxidase‑like activity, achieving a 26% higher maximum reaction velocity and a 46% lower Km than bare MnO2. The nanozyme enables ultrasensitive detection of cellular antioxidants such as ascorbic acid, glutathione...
Digital Intervention Aims to Alleviate Depression in Seniors
A new digital health platform designed for seniors aims to reduce depression by delivering AI‑driven cognitive‑behavioral therapy, real‑time mood monitoring, and caregiver notifications. In a 12‑week randomized trial involving 5,000 participants aged 65 and older, users experienced a 30% drop...
Assessing Viral Hepatitis Readiness in Vietnam and Philippines
A joint assessment by health ministries and WHO evaluated Vietnam and the Philippines' capacity to meet WHO’s 2030 viral hepatitis elimination targets. The study examined surveillance systems, treatment access, vaccination coverage, and financing mechanisms. Both countries showed progress in hepatitis...
Biorce Raises $52M to Support Global Rollout of Its AI Clinical Trial Platform
Barcelona‑based health AI firm Biorce closed a $52 million Series A round, led by DST Global Partners and supported by existing backers Norrsken VC, YZR Capital and Mustard Seed Maze. The financing brings total capital raised above $60 million and will fund the...
Modified FOLFIRINOX Plus Nivolumab in Pancreatic Cancer Trial
A phase II trial evaluated a modified FOLFIRINOX regimen combined with the PD‑1 inhibitor nivolumab in patients with advanced pancreatic ductal adenocarcinoma. The combination achieved a 38% overall response rate, surpassing historical FOLFIRINOX outcomes, with median progression‑free survival extending to...
European Law Changes Mean Drugmakers May Have to Grapple with Generic Competition Sooner
European regulators are preparing a suite of new laws that will tighten the timeline for generic and biosimilar entry, shortening data‑exclusivity periods and expanding patent‑linkage requirements. The measures aim to force originator drugmakers to confront competition earlier, potentially shaving 15‑20%...
Opinion: Pricing Transparency Is Coming to the Pharma Industry
The article argues that the pharmaceutical sector must abandon its long‑standing secrecy on drug pricing as recent U.S. executive orders intensify pressure for transparency. While companies cite R&D costs and complex payer negotiations, they rarely disclose how individual drug prices...
Psychedelics Space at a ‘Tipping Point’ as Compass, Definium Gear Up To File for Approval
Compass Pathways and Definium (formerly MindMed) are poised to file FDA applications for their psychedelic therapies—Compass' psilocybin‑based COMP360 for treatment‑resistant depression and Definium's LSD‑based MM120 for anxiety—following late‑stage Phase III readouts. Analysts predict filings by Q3 2025 and potential approvals by 2027,...
